CRP and non-small cell lung carcinoma: After the exclusion of 103 patients for whom baseline CRP was not available, and 8 patients with stage III NSCLC treated with consolidation durvalumab after definitive chemo-radiation therapy, 308 patients were included in the final analysis as outlined in online supplemental figure 1.